Varshita Srivastava is a second-year PhD student in the lab named, 'The Infectious Disease Research Laboratory,' at the Central University of Rajasthan. After passing three levels of screening on September 15, 2021, she was enrolled in the class of 2021. Varshita has been actively participating in several research projects in my lab since then, and during the covid epidemic, she worked with our team and owned a co authorship in the paper entitled-. “Identification of antiviral peptide inhibitors for receptor binding domain of SARS-CoV-2 omicron and its sub-variants: an in-silico approach” During the Monkeypox endemic, she successfully led a group and submitted her findings in the article entitled “Identification of FDA-approved drugs with triple targeting mode of action for the treatment of Monkeypox: a high throughput virtual screening study” and the draft after the first revision has already been submitted. Moreover, her second research work is under review, showing her research dedication. Varshita is a highly passionate, committed, ambitious, and creative girl. She is energetic, unique, diligent, motivated, industrious, and always eager to acquire new knowledge. Her zest for learning and for her career is inspiring. She has actively engaged in many departmental activities, conferences, and training since the beginning of her PhD degree. She works on multi-targeting medications to treat malaria and other infectious diseases. This demonstrates her significant interest in understanding the causes of the rapid epidemic as well as methods to control and deal with such acute catastrophes. These characteristics and her enthusiasm make her a viable option for your event.
Title : Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: A high throughput virtual screening study